Clarithromycin
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB01211 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 17 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | hyperamylasemia | KG + DL |
| 2 | polyclonal hyperviscosity syndrome | KG + DL |
| 3 | congenital analbuminemia | KG + DL |
| 4 | punctate epithelial keratoconjunctivitis | KG + DL |
| 5 | blood group incompatibility | KG + DL |
| 6 | premalignant hematological system disease | KG + DL |
| 7 | monoclonal gammopathy | KG + DL |
| 8 | septicemic plague | KG + DL |
| 9 | hematological disease associated with an acquired peripheral neuropathy | KG + DL |
| 10 | congenital hematological disorder | KG + DL |
| 11 | chronic tubotympanic suppurative otitis media | KG + DL |
| 12 | bubonic plague | KG + DL |
| 13 | exposure keratitis | KG + DL |
| 14 | conjunctivitis | KG + DL |
| 15 | hematopoietic and lymphoid system neoplasm | KG + DL |
| 16 | non-human animal disease | KG + DL |
| 17 | lymphogranuloma venereum | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.